Pfizer Inc. (NYSE: PFE) today announced positive topline results from the progression-free survival (PFS) analysis of the Phase 3 BREAKWATER study of BRAFTOVI ® (encorafenib) in combination with ...

At the time of the ORR analysis, the safety profile of Braftovi in combination with Lilly’s Erbitux and mFOLFOX6 remained consistent with the established safety profiles of each agent.

Pfizer has announced that its Braftovi (encorafenib) regimen significantly improved ... trial has been evaluating the drug in combination with Eli Lilly/Merck KGaA’s Erbitux (cetuximab) and mFOLFOX6 ...

The BREAKWATER trial, a randomized, active-controlled, open-label, multicenter study, compared the efficacy of BRAFTOVI with cetuximab and mFOLFOX6 against standard chemotherapy with or without ...

At the time of the ORR analysis, the safety profile of BRAFTOVI in combination with cetuximab and mFOLFOX6 continued to be consistent with the known safety profile of each respective agent.

NEW YORK, NY, USA I February 03, 2025 I Pfizer Inc. (NYSE: PFE) today announced positive topline results from the progression-free survival (PFS) analysis of the Phase 3 BREAKWATER study of BRAFTOVI ® ...

BRAFTOVI in combination with cetuximab and mFOLFOX6 showed statistically significant and clinically meaningful improvement in progression-free survival and overall survival in patients with ...